Friday, April 28, 2023, San Antonio, Texas, 12:15 PM – 1:45 PM Central Time (1:15 PM – 2:45 PM Eastern Time)

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation

Fifteenth Annual RTP Symposium Series Held During the Annual ONS Congress

Ovarian Cancer

 
Location
Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Program Schedule — Central Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — Lunch Meeting

Meeting Room
Texas Ballroom (Salons A-C) – Fourth Floor


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Courtney Arn, CNP
The James Cancer Hospital and Solove Research Institute
The Ohio State University
Columbus, Ohio

David M O'Malley, MD
Professor
Division Director, Gynecologic Oncology
The Ohio State University and The James Cancer Center
Columbus, Ohio


Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts

Jaclyn Shaver, MS, APRN, CNP, WHNP
Section of Gynecologic Oncology
Stephenson Cancer Center
OU Health
Oklahoma City, Oklahoma

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, GSK, Merck, Mersana Therapeutics Inc, and Novocure Inc during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
11:45 AM – 12:15 PM — Registration
12:15 PM – 1:45 PM — Educational Lunch Meeting

What I Tell My Patients About ...

Genetic Testing in Newly Diagnosed Advanced Ovarian Cancer (OC)

  • Incidence and clinical significance of BRCA mutations and other germline or somatic alterations, such as PALB2, RAD51C, RAD51D or ATM, in OC
  • Definition and frequency of homologous recombination deficiency (HRD) in OC; rationale for determining HRD status
  • Current role of next-generation sequencing and germline sequencing in advanced OC; similarities and differences among available genetic testing platforms
  • Utility of genetic counseling after an OC diagnosis

The Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Advanced OC

  • Mechanism of antitumor activity of PARP inhibitors and rationale for their use as maintenance therapy for patients with OC
  • Long-term findings from Phase III studies with olaparib, niraparib and olaparib/bevacizumab maintenance therapy for newly diagnosed OC
  • Clinical, biologic and practical factors affecting the selection of up-front olaparib, niraparib or olaparib/bevacizumab maintenance therapy
  • Early findings with niraparib/bevacizumab maintenance therapy after front-line platinum-based chemotherapy/bevacizumab; ongoing evaluation and potential clinical role

PARP Inhibitors for Relapsed/Refractory OC

  • Defining “platinum-sensitive” and “platinum-resistant” in patients with relapsed OC
  • Long-term follow-up, including overall survival findings, from pivotal trials evaluating niraparib, olaparib and rucaparib for platinum-sensitive and platinum-resistant recurrent OC
  • Patient- and disease-related factors contributing to the selection of a PARP inhibitor for relapsed OC; recent voluntary withdrawals of several indications for PARP inhibitors in the later-line setting
  • Key data documenting the clinical utility of rechallenge with a PARP inhibitor for patients who have experienced disease progression while receiving or after prior PARP inhibitor therapy; current role in practice

The Tolerability of PARP Inhibitors for Patients with OC

  • Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with OC
  • Optimal monitoring and management of common PARP inhibitor-related toxicities
  • Reported risk of long-term, serious side effects such as acute myeloid leukemia/myelodysplastic syndromes with PARP inhibitor therapy
  • Role of switching to an alternative PARP inhibitor for patients who are experiencing unacceptable toxicity

Other Practical Considerations with the Use of PARP Inhibitors for OC

  • Initial dosing and appropriate dose-modification strategies for approved PARP inhibitors
  • Optimal duration of PARP inhibitors in the maintenance setting
  • Importance of adherence among patients receiving long-term oral medications, including PARP inhibitors; strategies to encourage and assess adherence
  • Documented interactions between approved PARP inhibitors and other medications and supplements

Current and Future Role of Antibody-Drug Conjugates in OC Treatment

  • Mechanism of action of mirvetuximab soravtansine; frequency of and scientific rationale for targeting folate receptor alpha (FRα) in OC
  • Published research findings with mirvetuximab soravtansine in FRα-positive, platinum-resistant OC
  • Spectrum, frequency and severity of toxicities, including ocular events, reported with mirvetuximab soravtansine
  • Biologic rationale for targeting NaPi2b in OC; structural components and mechanism of antitumor activity of upifitamab rilsodotin (UpRi)
  • Initial efficacy observed with UpRi for heavily pretreated OC
  • Rates of commonly occurring adverse events, such as fatigue, nausea and increased AST, reported with UpRi
  • Ongoing studies evaluating UpRi for platinum-resistant and platinum-sensitive OC

Other Promising Investigational Agents and Strategies for Advanced OC

  • Mechanism of action of tumor treating fields (TTFields) and biologic rationale for their investigation in OC
  • Available efficacy and safety data with and ongoing evaluation of TTFields in combination with chemotherapy for advanced OC
  • Patient experience undergoing treatment with TTFields; prevalence of skin toxicities and other practical considerations
  • Emerging positive findings with the combination of olaparib, durvalumab, chemotherapy and bevacizumab followed by olaparib, durvalumab and bevacizumab maintenance for patients with previously untreated OC without BRCA mutations
  • Available data with and ongoing Phase III trials evaluating other PARP inhibitors in combination with anti-PD-1/PD-L1 antibodies with or without bevacizumab for OC
  • Other promising novel agents and strategies under investigation

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand the importance of genetic testing for women with newly diagnosed OC, and counsel patients about the clinical relevance of test results.
  • Appreciate published research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and use this insight to explain personalized treatment recommendations to patients.
  • Evaluate available clinical trial results with and approved indications for PARP inhibitors and agents targeting folate receptor alpha for patients with recurrent OC.
  • Recognize the rationale for targeting sodium-dependent phosphate transport protein 2b in OC, and consider available research findings with and the potential role of novel approaches to therapeutically exploit this biomarker.
  • Describe the scientific rationale for the use of tumor treating fields as a therapeutic approach for patients with OC, and appraise the available efficacy and safety data with this strategy in combination with chemotherapy for recurrent, advanced disease.
  • Assess the toxicities associated with PARP inhibitors and other novel agents for OC, and offer patients supportive management strategies to minimize and ameliorate these side effects.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. https://www.researchtopractice.com/Meetings/ONS2023/Ovarian/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Shaver has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Arn — Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, ImmunoGen Inc, Merck, Seagen Inc. Dr O'Malley — Advisory Committee and Consulting Agreements (Personal Fees): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Novartis, Novocure Inc, OncoC4, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research (Institution Received Funds): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Clovis Oncology, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, Novartis, Novocure Inc, OncoC4 Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Rubius Therapeutics, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Nonrelevant Financial Relationship: GOG Foundation Inc, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG, SWOG. Dr Penson — Advisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, Novocure Inc, Roche Laboratories Inc, Sutro Biopharma, VBL Therapeutics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi, Tesaro, A GSK Company, VBL Therapeutics; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Nonrelevant Financial Relationship: BMJ Publishing Group Ltd, Elsevier, UptoDate, Wiley-Blackwell, Wolters Kluwer Health.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, Mersana Therapeutics Inc, and Novocure Inc.

Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Meeting Room:
Texas Ballroom (Salons A-C) – Fourth Floor

The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.

​ ​ ​
IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 11:45 AM Central Time on Friday, April 28th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.

Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability.

LIVE WEBCAST registration open to all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.